AlzeCure releases new data on its pain project ACD440

Swedish CNS specialist AlzeCure Pharma (FN STO: ALZCUR) saw its shares gain 6.5% to 3.78 kronor this morning as it presented Phase II data on its lead clinical drug candidate in pain, ACD440, at the international pain conference, NeuPSIG 2025.

“Our data from the phase II study with ACD440 showed that the substance reduces temperature-induced pain by approximately 50%, a significant and clinically relevant reduction. These positive data are in line with the results from the phase Ib study and we have also demonstrated proof-of-mechanism in patients,” said Dr Märta Segerdahl, project leader and chief medical officer at AlzeCure Pharma.